Allakos News

Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions

Yahoo Finance04:02

NOTV, BFRI and CPOP Among Pre-market Losers

Seeking AlphaMay 10 20:30

Analysts Have Conflicting Sentiments on These Healthcare Companies: Electrocore (ECOR), Disc Medicine (IRON) and Allakos (ALLK)

TipRanksMay 10 20:10

Barclays Sticks to Its Sell Rating for Allakos (ALLK)

TipRanksMay 10 18:05

Allakos Buy Rating: Clinical Promise and Financial Stability Drive Positive Outlook

TipRanksMay 10 12:55

Allakos | 10-Q: Quarterly report

Futu NewsMay 10 05:15 · Announcements

Allakos Q1 2024 GAAP EPS $(0.81) Misses $(0.44) Estimate

Allakos (NASDAQ:ALLK) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.44) by 84.09 percent. This is a 65.31 percent decrease over losses of $(0.49) pe

BenzingaMay 10 04:54

Allakos 1Q Loss/Shr 81c >ALLK

Allakos 1Q Loss/Shr 81c >ALLK

Dow JonesMay 10 04:02

Press Release: Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology com

Dow JonesMay 10 04:02

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out

BenzingaMay 2 04:31

Market Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical Developments

TipRanksApr 24 12:25

Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program

TipRanksMar 19 13:38

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

Yahoo FinanceMar 16 17:31

Hold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 Developments

TipRanksMar 15 20:05

Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Century Therapeutics (IPSC)

TipRanksMar 15 19:10

Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)

TipRanksMar 15 12:40

TD Cowen Remains a Hold on Allakos (ALLK)

TipRanksMar 15 06:35

Allakos Q4 EPS $(0.71) Misses $(0.47) Estimate

Allakos (NASDAQ:ALLK) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.47) by 51.06 percent. This is a 42 percent decrease over losses of $(0.50) per s

BenzingaMar 15 04:05

Allakos: Ended 4Q With Approximately $170.8 M in Cash, Cash Equivalents and Investments >ALLK

Allakos: Ended 4Q With Approximately $170.8 M in Cash, Cash Equivalents and Investments >ALLK

Dow JonesMar 15 04:05

Allakos: As a Result of the Restructuring Expects Cash Runway to Extend Into Mid-2026 >ALLK

Allakos: As a Result of the Restructuring Expects Cash Runway to Extend Into Mid-2026 >ALLK

Dow JonesMar 15 04:04